OS Therapies names Kerry Clem as CCO, Frank Knuettel II as CFO
Both hires, effective September 29, 2026, are tied to commercial preparations for Herlystic (OST-HER2; daznelimgene lisbac) ahead of expected regulatory decisions in the U.K., U.S., and Europe.
SEC filing